Pulaski BA - Search Results

1

Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease.

Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Danna EA, et al. Among authors: pulaski ba. Cancer Res. 2004 Mar 15;64(6):2205-11. doi: 10.1158/0008-5472.can-03-2646. Cancer Res. 2004. PMID: 15026364

2

Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma.

Pulaski BA, Smyth MJ, Ostrand-Rosenberg S. Pulaski BA, et al. Cancer Res. 2002 Aug 1;62(15):4406-12. Cancer Res. 2002. PMID: 12154047

3

Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines.

Pulaski BA, Ostrand-Rosenberg S. Pulaski BA, et al. Cancer Res. 1998 Apr 1;58(7):1486-93. Cancer Res. 1998. PMID: 9537252

4

Tumor antigen presentation: changing the rules.

Armstrong TD, Pulaski BA, Ostrand-Rosenberg S. Armstrong TD, et al. Among authors: pulaski ba. Cancer Immunol Immunother. 1998 Apr;46(2):70-4. doi: 10.1007/s002620050463. Cancer Immunol Immunother. 1998. PMID: 9558001 Free PMC article. Review.

5

Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.

Pulaski BA, Clements VK, Pipeling MR, Ostrand-Rosenberg S. Pulaski BA, et al. Cancer Immunol Immunother. 2000 Apr;49(1):34-45. doi: 10.1007/s002620050024. Cancer Immunol Immunother. 2000. PMID: 10782864 Free PMC article.

6

Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model.

Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Pulaski BA, et al. Cancer Res. 2000 May 15;60(10):2710-5. Cancer Res. 2000. PMID: 10825145

7

Mouse 4T1 breast tumor model.

Pulaski BA, Ostrand-Rosenberg S. Pulaski BA, et al. Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.2. doi: 10.1002/0471142735.im2002s39. Curr Protoc Immunol. 2001. PMID: 18432775

8

Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines.

Ostrand-Rosenberg S, Pulaski BA, Armstrong TD, Clements VK. Ostrand-Rosenberg S, et al. Among authors: pulaski ba. Adv Exp Med Biol. 1998;451:259-64. doi: 10.1007/978-1-4615-5357-1_42. Adv Exp Med Biol. 1998. PMID: 10026883 No abstract available.

9

Cell-based vaccines for the stimulation of immunity to metastatic cancers.

Ostrand-Rosenberg S, Pulaski BA, Clements VK, Qi L, Pipeling MR, Hanyok LA. Ostrand-Rosenberg S, et al. Among authors: pulaski ba. Immunol Rev. 1999 Aug;170:101-14. doi: 10.1111/j.1600-065x.1999.tb01332.x. Immunol Rev. 1999. PMID: 10566145 Review.

10

Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.

Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG. Pulaski BA, et al. Cancer Res. 1993 May 1;53(9):2112-7. Cancer Res. 1993. PMID: 8097675

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters